These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12402208)

  • 61. Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children.
    Nurkka A; MacLennan J; Jäntti V; Obaro S; Greenwood B; Käyhty H
    Vaccine; 2000 Oct; 19(4-5):547-56. PubMed ID: 11027820
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood.
    MacLennan J; Obaro S; Deeks J; Williams D; Pais L; Carlone G; Moxon R; Greenwood B
    Vaccine; 1999 Aug; 17(23-24):3086-93. PubMed ID: 10462244
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The duration of the antibody response to meningococcal vaccination in an African village.
    Greenwood BM; Whittle HC; Bradley AK; Fayet MT; Gilles HM
    Trans R Soc Trop Med Hyg; 1980; 74(6):756-60. PubMed ID: 6782720
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Optimal inoculation doses of meningococcal chemical polyvalent ABC-vaccine for immunizing children of different ages. II. A study of the immunological effectiveness of different doses of the preparation].
    Ganzenko VP; Sumarokov AA; Nikonova VA; Filippov IuV; Valcarcel Novo M
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Apr; (4):23-6. PubMed ID: 6408855
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Specific immunological reactivity in generalized forms of meningococcal infection in children].
    Korzhueva NA; Rybalko DI; Naglenko VP; Zinchenko AP
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Aug; (8):110-4. PubMed ID: 6435355
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Meningococcal infections. 5. Duration of polysaccharide-vaccine-induced antibody.
    Artenstein MS
    Bull World Health Organ; 1971; 45(3):291-3. PubMed ID: 4947213
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.
    Micoli F; Stefanetti G; MacLennan CA
    Front Mol Biosci; 2023; 10():1201693. PubMed ID: 37261327
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy.
    Neri A; Fabiani M; Barbui AM; Vocale C; Miglietta A; Fazio C; Carannante A; Palmieri A; Vacca P; Ambrosio L; Stefanelli P
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632534
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Seroprevalence of meningococcal serogroup C bactericidal antibodies in the Portuguese population, a decade after vaccine introduction in the National Immunisation Programme.
    Gonçalves P; Sáez-López E; Carneiro S; Simões MJ
    PLoS One; 2021; 16(4):e0250103. PubMed ID: 33857245
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta.
    Pace D; Gauci C; Barbara C
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1885-1897. PubMed ID: 32418063
    [TBL] [Abstract][Full Text] [Related]  

  • 71. UPDATE ON THE USE OF QUADRIVALENT CONJUGATE MENINGOCOCCAL VACCINES: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).
    Warshawsky TSWPBDB;
    Can Commun Dis Rep; 2013 Jan; 39(ACS-1):1-40. PubMed ID: 31697281
    [No Abstract]   [Full Text] [Related]  

  • 72. Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12-23 months in China.
    Hu J; Li H; Chu K; Liang Q; Li J; Luo L; Hu Y; Meng F; Zhu F
    Hum Vaccin Immunother; 2019; 15(12):2952-2959. PubMed ID: 31348731
    [No Abstract]   [Full Text] [Related]  

  • 73. [From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine].
    Abad R; Martinón-Torres F; Santolaya ME; Banzhoff A; González-Inchausti C; Graña MG; Vázquez JA
    Rev Esp Quimioter; 2019 Jun; 32(3):208-216. PubMed ID: 31148440
    [TBL] [Abstract][Full Text] [Related]  

  • 74. What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK Experience.
    Findlow H; Borrow R
    Paediatr Drugs; 2016 Apr; 18(2):83-7. PubMed ID: 26913860
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.
    Holme D; Findlow H; Sow SO; Idoko OT; Preziosi MP; Carlone G; Plikaytis BD; Borrow R
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S563-9. PubMed ID: 26553689
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
    Tapia MD; Findlow H; Idoko OT; Preziosi MP; Kulkarni PS; Enwere GC; Elie C; Parulekar V; Sow SO; Haidara FC; Diallo F; Doumbia M; Akinsola AK; Adegbola RA; Kampmann B; Chaumont J; Martellet L; Marchetti E; Viviani S; Tang Y; Plikaytis BD; LaForce FM; Carlone G; Borrow R
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S514-20. PubMed ID: 26553683
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Human Infant Memory B Cell and CD4+ T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine.
    Fuery A; Richmond PC; Currie AJ
    PLoS One; 2015; 10(7):e0133126. PubMed ID: 26191794
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?
    Findlow H; Borrow R
    Hum Vaccin Immunother; 2015; 11(6):1501-6. PubMed ID: 25912095
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
    Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
    BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Global practices of meningococcal vaccine use and impact on invasive disease.
    Ali A; Jafri RZ; Messonnier N; Tevi-Benissan C; Durrheim D; Eskola J; Fermon F; Klugman KP; Ramsay M; Sow S; Zhujun S; Bhutta Z; Abramson J
    Pathog Glob Health; 2014 Jan; 108(1):11-20. PubMed ID: 24548156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.